By Cort Johnson in Health Rising.
Research funding for chronic fatigue syndrome (ME/CFS) has been poor at best but clinical trials have elicited a wholly different degree of disappointment altogether. Few clinical trials are ever done and those often involve alternative approaches. The six active clinical trials listed in clinicaltrials.gov, for instance, include treatments like acupuncture, moxibustion, oral rehydration and CoQ10.
That makes it shocking to see a “new” drug – a drug not being used in other diseases – get a clinical trial in ME/CFS. It wasn’t supposed to happen this way. First, it’s been assumed that repurposed drugs – drugs already in use in other disease – would be tested in ME/CFS to improve symptoms – and only later, as we understood the disease better, would we get to a drug that gets at the core problems in ME/CFS. This group believes they have a drug that gets at the core of ME/CFS now, and in the first quarter of this year they expect to test that drug.
Over the next month, Health Rising will be publishing a 3 or 4-part blog series telling the story of the small group of researchers that are bringing a drug to ME/CFS they believe could get at the core of this disease.
The drug itself is highly experimental and the researchers behind it come from the biotechnology and drug development fields. They stumbled on ME/CFS by chance, but when they did, the light bulbs went on. For the past year or two, they’ve devoted their time to understanding ME/CFS and getting to the place where a clinical trial can take place.
To read the rest of this story, click on the link below: